Abstract
The availability of antemortem biomarkers for Alzheimer's disease (AD) enables monitoring the evolution of neurodegenerative processes in real time. Pittsburgh compound B (PIB) positron emission tomography (PET) was used to select participants in the Mayo Clinic Study of Aging and the Mayo Alzheimer's Disease Research Center with elevated β-amyloid, designated as “A+,” and hippocampal volume and 18fluorodeoxyglucose (FDG) positron emission tomography were used to characterize participants as having evidence of neurodegeneration (“N+”) at the baseline evaluation. There were 145 clinically normal (CN) A+ individuals, 62 persons with mild cognitive impairment (MCI) who were A+ and 20 with A+ AD dementia. Over a period of 1–6 years, MCI A+N+ individuals showed declines in medial temporal, lateral temporal, lateral parietal, and to a lesser extent, medial parietal regions for both FDG standardized uptake value ratio and gray matter volume that exceeded declines seen in the CN A+N+ group. The AD dementia group showed declines in the same regions on FDG standardized uptake value ratio and gray matter volume with rates that exceeded that in MCI A+N+. Expansion of regional involvement and faster rate of neurodegeneration characterizes progression in the AD pathway.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 32-42 |
| Number of pages | 11 |
| Journal | Neurobiology of Aging |
| Volume | 46 |
| DOIs | |
| State | Published - Oct 1 2016 |
Fingerprint
Keywords
- Alzheimer's disease
- FDG PET imaging
- Longitudinal study
- MR imaging
- PIB PET imaging
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)
- Aging
- Developmental Biology
- Geriatrics and Gerontology
Cite this
Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. / Knopman, David S; Jack, Clifford R Jr.; Lundt, Emily S.; Weigand, Stephen D.; Vemuri, Prashanthi D; Lowe, Val; Kantarci, Kejal M; Gunter, Jeffrey L.; Senjem, Matthew L.; Mielke, Michelle M; Machulda, Mary Margaret; Roberts, Rosebud O; Boeve, Bradley F; Jones, David T; Petersen, Ronald Carl.
In: Neurobiology of Aging, Vol. 46, 01.10.2016, p. 32-42.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum
AU - Knopman, David S
AU - Jack, Clifford R Jr.
AU - Lundt, Emily S.
AU - Weigand, Stephen D.
AU - Vemuri, Prashanthi D
AU - Lowe, Val
AU - Kantarci, Kejal M
AU - Gunter, Jeffrey L.
AU - Senjem, Matthew L.
AU - Mielke, Michelle M
AU - Machulda, Mary Margaret
AU - Roberts, Rosebud O
AU - Boeve, Bradley F
AU - Jones, David T
AU - Petersen, Ronald Carl
PY - 2016/10/1
Y1 - 2016/10/1
N2 - The availability of antemortem biomarkers for Alzheimer's disease (AD) enables monitoring the evolution of neurodegenerative processes in real time. Pittsburgh compound B (PIB) positron emission tomography (PET) was used to select participants in the Mayo Clinic Study of Aging and the Mayo Alzheimer's Disease Research Center with elevated β-amyloid, designated as “A+,” and hippocampal volume and 18fluorodeoxyglucose (FDG) positron emission tomography were used to characterize participants as having evidence of neurodegeneration (“N+”) at the baseline evaluation. There were 145 clinically normal (CN) A+ individuals, 62 persons with mild cognitive impairment (MCI) who were A+ and 20 with A+ AD dementia. Over a period of 1–6 years, MCI A+N+ individuals showed declines in medial temporal, lateral temporal, lateral parietal, and to a lesser extent, medial parietal regions for both FDG standardized uptake value ratio and gray matter volume that exceeded declines seen in the CN A+N+ group. The AD dementia group showed declines in the same regions on FDG standardized uptake value ratio and gray matter volume with rates that exceeded that in MCI A+N+. Expansion of regional involvement and faster rate of neurodegeneration characterizes progression in the AD pathway.
AB - The availability of antemortem biomarkers for Alzheimer's disease (AD) enables monitoring the evolution of neurodegenerative processes in real time. Pittsburgh compound B (PIB) positron emission tomography (PET) was used to select participants in the Mayo Clinic Study of Aging and the Mayo Alzheimer's Disease Research Center with elevated β-amyloid, designated as “A+,” and hippocampal volume and 18fluorodeoxyglucose (FDG) positron emission tomography were used to characterize participants as having evidence of neurodegeneration (“N+”) at the baseline evaluation. There were 145 clinically normal (CN) A+ individuals, 62 persons with mild cognitive impairment (MCI) who were A+ and 20 with A+ AD dementia. Over a period of 1–6 years, MCI A+N+ individuals showed declines in medial temporal, lateral temporal, lateral parietal, and to a lesser extent, medial parietal regions for both FDG standardized uptake value ratio and gray matter volume that exceeded declines seen in the CN A+N+ group. The AD dementia group showed declines in the same regions on FDG standardized uptake value ratio and gray matter volume with rates that exceeded that in MCI A+N+. Expansion of regional involvement and faster rate of neurodegeneration characterizes progression in the AD pathway.
KW - Alzheimer's disease
KW - FDG PET imaging
KW - Longitudinal study
KW - MR imaging
KW - PIB PET imaging
UR - http://www.scopus.com/inward/record.url?scp=84978208857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978208857&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2016.06.003
DO - 10.1016/j.neurobiolaging.2016.06.003
M3 - Article
C2 - 27460147
AN - SCOPUS:84978208857
VL - 46
SP - 32
EP - 42
JO - Neurobiology of Aging
JF - Neurobiology of Aging
SN - 0197-4580
ER -